Note to users. If you're seeing this message, it means that your browser cannot find this page's style/presentation instructions -- or possibly that you are using a browser that does not support current Web standards. Find out more about why this message is appearing, and what you can do to make your experience of our site the best it can be.

Site Tools

  • AAAS
  • Subscribe
  • Feedback

Site Search

Search Advanced

Science 25 February 2000:
Vol. 287. no. 5457, pp. 1503 - 1506
DOI: 10.1126/science.287.5457.1503
Prev | Table of Contents | Next

Reports

Porphyrin and Phthalocyanine Antiscrapie Compounds

Suzette A. Priola, * Anne Raines, Winslow S. Caughey

The transmissible spongiform encephalopathies (TSEs) are fatal, neurodegenerative diseases for which no effective treatments are available. The likelihood that a bovine form of TSE has crossed species barriers and infected humans underscores the urgent need to identify anti-TSE drugs. Certain cyclic tetrapyrroles (porphyrins and phthalocyanines) have recently been shown to inhibit the in vitro formation of PrP-res, a protease-resistant protein critical for TSE pathogenesis. We now report that treatment of TSE-infected animals with three such compounds increased survival time from 50 to 300%. The significant inhibition of TSE disease by structurally dissimilar tetrapyrroles identifies these compounds as anti-TSE drugs.

Laboratory of Persistent Viral Diseases, Rocky Mountain Laboratories, National Institute of Allergy and Infectious Diseases, National Institutes of Health, Hamilton, MT 59840, USA.
*   To whom correspondence should be addressed. E-mail: spriola{at}nih.gov

Read the Full Text


THIS ARTICLE HAS BEEN CITED BY OTHER ARTICLES:
Effect of Transplantation of Bone Marrow-Derived Mesenchymal Stem Cells on Mice Infected with Prions.
C.-H. Song, O. Honmou, N. Ohsawa, K. Nakamura, H. Hamada, H. Furuoka, R. Hasebe, and M. Horiuchi (2009)
J. Virol. 83, 5918-5927
   Abstract »    Full Text »    PDF »
Effect of intraventricular infusion of anti-prion protein monoclonal antibodies on disease progression in prion-infected mice.
C.-H. Song, H. Furuoka, C.-L. Kim, M. Ogino, A. Suzuki, R. Hasebe, and M. Horiuchi (2008)
J. Gen. Virol. 89, 1533-1544
   Abstract »    Full Text »    PDF »
Hemin Interactions and Alterations of the Subcellular Localization of Prion Protein.
K. S. Lee, L. D. Raymond, B. Schoen, G. J. Raymond, L. Kett, R. A. Moore, L. M. Johnson, L. Taubner, J. O. Speare, H. A. Onwubiko, et al. (2007)
J. Biol. Chem. 282, 36525-36533
   Abstract »    Full Text »    PDF »
Cyclic Tetrapyrrole Sulfonation, Metals, and Oligomerization in Antiprion Activity.
W. S. Caughey, S. A. Priola, D. A. Kocisko, L. D. Raymond, A. Ward, and B. Caughey (2007)
Antimicrob. Agents Chemother. 51, 3887-3894
   Abstract »    Full Text »    PDF »
Cyclodextrins Inhibit Replication of Scrapie Prion Protein in Cell Culture.
M. Prior, S. Lehmann, M.-S. Sy, B. Molloy, and H. E. M. McMahon (2007)
J. Virol. 81, 11195-11207
   Abstract »    Full Text »    PDF »
Nonpsychoactive Cannabidiol Prevents Prion Accumulation and Protects Neurons against Prion Toxicity.
S. Dirikoc, S. A. Priola, M. Marella, N. Zsurger, and J. Chabry (2007)
J. Neurosci. 27, 9537-9544
   Abstract »    Full Text »    PDF »
Hot spots in prion protein for pathogenic conversion.
K. Kuwata, N. Nishida, T. Matsumoto, Y. O. Kamatari, J. Hosokawa-Muto, K. Kodama, H. K. Nakamura, K. Kimura, M. Kawasaki, Y. Takakura, et al. (2007)
PNAS 104, 11921-11926
   Abstract »    Full Text »    PDF »
A systematic review of prion therapeutics in experimental models.
C. R Trevitt and J. Collinge (2006)
Brain 129, 2241-2265
   Abstract »    Full Text »    PDF »
Potent Antiscrapie Activities of Degenerate Phosphorothioate Oligonucleotides.
D. A. Kocisko, A. Vaillant, K. S. Lee, K. M. Arnold, N. Bertholet, R. E. Race, E. A. Olsen, J.-M. Juteau, and B. Caughey (2006)
Antimicrob. Agents Chemother. 50, 1034-1044
   Abstract »    Full Text »    PDF »
Dequalinium-induced Protofibril Formation of {alpha}-Synuclein.
C.-H. Lee, H. J. Kim, J.-H. Lee, H.-J. Cho, J. Kim, K. C. Chung, S. Jung, and S. R. Paik (2006)
J. Biol. Chem. 281, 3463-3472
   Abstract »    Full Text »    PDF »
A Porphyrin Increases Survival Time of Mice after Intracerebral Prion Infection.
D. A. Kocisko, W. S. Caughey, R. E. Race, G. Roper, B. Caughey, and J. D. Morrey (2006)
Antimicrob. Agents Chemother. 50, 759-761
   Abstract »    Full Text »    PDF »
Inhibition of Protease-Resistant Prion Protein Formation in a Transformed Deer Cell Line Infected with Chronic Wasting Disease.
G. J. Raymond, E. A. Olsen, K. S. Lee, L. D. Raymond, P. K. Bryant III, G. S. Baron, W. S. Caughey, D. A. Kocisko, L. E. McHolland, C. Favara, et al. (2006)
J. Virol. 80, 596-604
   Abstract »    Full Text »    PDF »
Mefloquine, an Antimalaria Drug with Antiprion Activity In Vitro, Lacks Activity In Vivo.
D. A. Kocisko and B. Caughey (2006)
J. Virol. 80, 1044-1046
   Abstract »    Full Text »    PDF »
Charged bipolar suramin derivatives induce aggregation of the prion protein at the cell surface and inhibit PrPSc replication.
M. Nunziante, C. Kehler, E. Maas, M. U. Kassack, M. Groschup, and H. M. Schatzl (2005)
J. Cell Sci. 118, 4959-4973
   Abstract »    Full Text »    PDF »
Systematic Identification of Antiprion Drugs by High-Throughput Screening Based on Scanning for Intensely Fluorescent Targets.
U. Bertsch, K. F. Winklhofer, T. Hirschberger, J. Bieschke, P. Weber, F. U. Hartl, P. Tavan, J. Tatzelt, H. A. Kretzschmar, and A. Giese (2005)
J. Virol. 79, 7785-7791
   Abstract »    Full Text »    PDF »
Screening of 145 Anti-PrP Monoclonal Antibodies for Their Capacity to Inhibit PrPSc Replication in Infected Cells.
C. Feraudet, N. Morel, S. Simon, H. Volland, Y. Frobert, C. Creminon, D. Vilette, S. Lehmann, and J. Grassi (2005)
J. Biol. Chem. 280, 11247-11258
   Abstract »    Full Text »    PDF »
Inhibition of Heparin-induced Tau Filament Formation by Phenothiazines, Polyphenols, and Porphyrins.
S. Taniguchi, N. Suzuki, M. Masuda, S.-i. Hisanaga, T. Iwatsubo, M. Goedert, and M. Hasegawa (2005)
J. Biol. Chem. 280, 7614-7623
   Abstract »    Full Text »    PDF »
Cell-surface retention of PrPC by anti-PrP antibody prevents protease-resistant PrP formation.
C.-L. Kim, A. Karino, N. Ishiguro, M. Shinagawa, M. Sato, and M. Horiuchi (2004)
J. Gen. Virol. 85, 3473-3482
   Abstract »    Full Text »    PDF »
Phospholipase A2 Inhibitors or Platelet-activating Factor Antagonists Prevent Prion Replication.
C. Bate, S. Reid, and A. Williams (2004)
J. Biol. Chem. 279, 36405-36411
   Abstract »    Full Text »    PDF »
Evaluation of new cell culture inhibitors of protease-resistant prion protein against scrapie infection in mice.
D. A. Kocisko, J. D. Morrey, R. E. Race, J. Chen, and B. Caughey (2004)
J. Gen. Virol. 85, 2479-2483
   Abstract »    Full Text »    PDF »
Amyloid imaging probes are useful for detection of prion plaques and treatment of transmissible spongiform encephalopathies.
K. Ishikawa, K. Doh-ura, Y. Kudo, N. Nishida, I. Murakami-Kubo, Y. Ando, T. Sawada, and T. Iwaki (2004)
J. Gen. Virol. 85, 1785-1790
   Abstract »    Full Text »    PDF »
Cationic phosphorus-containing dendrimers reduce prion replication both in cell culture and in mice infected with scrapie.
J. Solassol, C. Crozet, V. Perrier, J. Leclaire, F. Beranger, A.-M. Caminade, B. Meunier, D. Dormont, J.-P. Majoral, and S. Lehmann (2004)
J. Gen. Virol. 85, 1791-1799
   Abstract »    Full Text »    PDF »
Quinoline Derivatives Are Therapeutic Candidates for Transmissible Spongiform Encephalopathies.
I. Murakami-Kubo, K. Doh-ura, K. Ishikawa, S. Kawatake, K. Sasaki, J.-i. Kira, S. Ohta, and T. Iwaki (2004)
J. Virol. 78, 1281-1288
   Abstract »    Full Text »    PDF »
De novo designed cyclic-peptide heme complexes.
M. M. Rosenblatt, J. Wang, and K. S. Suslick (2003)
PNAS 100, 13140-13145
   Abstract »    Full Text »    PDF »
Games Played by Rogue Proteins in Prion Disorders and Alzheimer's Disease.
A. Aguzzi and C. Haass (2003)
Science 302, 814-818
   Abstract »    Full Text »    PDF »
Depleting Neuronal PrP in Prion Infection Prevents Disease and Reverses Spongiosis.
G. Mallucci, A. Dickinson, J. Linehan, P.-C. Klohn, S. Brandner, and J. Collinge (2003)
Science 302, 871-874
   Abstract »    Full Text »    PDF »
New Inhibitors of Scrapie-Associated Prion Protein Formation in a Library of 2,000 Drugs and Natural Products.
D. A. Kocisko, G. S. Baron, R. Rubenstein, J. Chen, S. Kuizon, and B. Caughey (2003)
J. Virol. 77, 10288-10294
   Abstract »    Full Text »    PDF »
Evaluation of Quinacrine Treatment for Prion Diseases.
A. Barret, F. Tagliavini, G. Forloni, C. Bate, M. Salmona, L. Colombo, A. De Luigi, L. Limido, S. Suardi, G. Rossi, et al. (2003)
J. Virol. 77, 8462-8469
   Abstract »    Full Text »    PDF »
Specific inhibition of pathological prion protein accumulation by small interfering RNAs.
N. Daude, M. Marella, and J. Chabry (2003)
J. Cell Sci. 116, 2775-2779
   Abstract »    Full Text »    PDF »
Approaches to prophylaxis and therapy: An investigation into prion disease diversity.
D. Dormont (2003)
Br. Med. Bull. 66, 281-292
   Abstract »    Full Text »    PDF »
Inhibition of Protease-Resistant Prion Protein Accumulation In Vitro by Curcumin.
B. Caughey, L. D. Raymond, G. J. Raymond, L. Maxson, J. Silveira, and G. S. Baron (2003)
J. Virol. 77, 5499-5502
   Abstract »    Full Text »    PDF »
Protein Conformation and Diagnostic Tests: The Prion Protein.
B. J. Bennion and V. Daggett (2002)
Clin. Chem. 48, 2105-2114
   Abstract »    Full Text »    PDF »
Dominant-negative inhibition of prion replication in transgenic mice.
V. Perrier, K. Kaneko, J. Safar, J. Vergara, P. Tremblay, S. J. DeArmond, F. E. Cohen, S. B. Prusiner, and A. C. Wallace (2002)
PNAS 99, 13079-13084
   Abstract »    Full Text »    PDF »
Tetracyclines affect prion infectivity.
G. Forloni, S. Iussich, T. Awan, L. Colombo, N. Angeretti, L. Girola, I. Bertani, G. Poli, M. Caramelli, M. Grazia Bruzzone, et al. (2002)
PNAS 99, 10849-10854
   Abstract »    Full Text »    PDF »
Immunization Delays the Onset of Prion Disease in Mice.
E. M. Sigurdsson, D. R. Brown, M. Daniels, R. J. Kascsak, R. Kascsak, R. Carp, H. C. Meeker, B. Frangione, and T. Wisniewski (2002)
Am. J. Pathol. 161, 13-17
   Abstract »    Full Text »    PDF »
Drug therapy in human and experimental transmissible spongiform encephalopathy.
P. Brown (2002)
Neurology 58, 1720-1725
   Abstract »    Full Text »    PDF »
Acridine and phenothiazine derivatives as pharmacotherapeutics for prion disease.
C. Korth, B. C. H. May, F. E. Cohen, and S. B. Prusiner (2001)
PNAS 98, 9836-9841
   Abstract »    Full Text »    PDF »
Scrapie prion protein accumulation by scrapie-infected neuroblastoma cells abrogated by exposure to a prion protein antibody.
M. Enari, E. Flechsig, and C. Weissmann (2001)
PNAS
   Abstract »    Full Text »    PDF »
Neurodegenerative Diseases and Prions.
S. B. Prusiner (2001)
N. Engl. J. Med. 344, 1516-1526
   Full Text »    PDF »
Branched Polyamines Cure Prion-Infected Neuroblastoma Cells.
S. Supattapone, H. Wille, L. Uyechi, J. Safar, P. Tremblay, F. C. Szoka, F. E. Cohen, S. B. Prusiner, and M. R. Scott (2001)
J. Virol. 75, 3453-3461
   Abstract »    Full Text »
Inhibition of Interactions and Interconversions of Prion Protein Isoforms by Peptide Fragments from the C-terminal Folded Domain.
M. Horiuchi, G. S. Baron, L.-W. Xiong, and B. Caughey (2001)
J. Biol. Chem. 276, 15489-15497
   Abstract »    Full Text »    PDF »
Scrapie prion protein accumulation by scrapie-infected neuroblastoma cells abrogated by exposure to a prion protein antibody.
M. Enari, E. Flechsig, and C. Weissmann (2001)
PNAS 98, 9295-9299
   Abstract »    Full Text »    PDF »


To Advertise     Find Products

Science. ISSN 0036-8075 (print), 1095-9203 (online)